Arum Therapeutics Inc
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Arum Therapeutics Inc - overview
Location
Seoul, -, South Korea
Primary Industry
Biotechnology
About
Based in Seoul, South Korea, and founded in 2019, Arum Therapeutics is a pharmaceutical company that focuses on the development of medicinal chemistry based on synthetic small molecules. The company's CEO and founder, Taegon Baik graduated from the University of Konkuk and served as head of the New Drug Discovery center at CJ CheilJedang. The company is building up pipelines in cancer and rare disease. It focuses on the development of target-based antiviral agents for Asthma and COPD exacerbation, anticancer immunotherapy, and mono or combination anticancer agents.
Current Investors
AJU IB Investment, KDB Capital, SBI Investment
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.arumtherapeutics.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Arum Therapeutics Inc - financials
| Fiscal Year Ended | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|
| Revenue (USD) | - | 114,795,000 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - |
| EBITDA (USD) | - | - | - | - | - |
| Operating Income (USD) | (3,764,000) | (541,098,000) | - | - | - |
| Operating Margin | - | (471.4%) | - | - | - |
| % EBITDA Margin | - | - | - | - | - |
| NET Income (USD) | (3,764,000) | (548,543,000) | - | - | - |
| % Net Margin | - | (477.8%) | - | - | - |
Arum Therapeutics Inc - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.